Inhibition of xCT Suppresses Melanoma progress

Tumor cells increase glutamate release through the cystine/glutamate transporter xCT to balance oxidative homeostasis in tumor cells and promote tumor progression. Here, we demonstrated that although inhibition of xCT either by pharmacological inhibitor (sulfasalazine, SAS), approved by FDA for inflammatory diseases, or genetic knockdown induced ROS-related death in melanoma cells. Taken together, our results reveal that inhibition of xCT by SAS is a promising therapeutic strategy for melanoma. Overall design: mRNA profiles of 3 replicated vehicle and 3 replicated 500µm SAS-treated B16F10 melanoma cells for 24 hours